Lilly’s £279 million investment set to boost UK life sciences sector, says analyst

19 December 2024

US pharma major Eli Lilly (NYSE: LLY) has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London.

The initiative is set to accelerate early-stage ventures and spearhead advancements in obesity treatments, invigorating the UK life sciences sector, says pharma analytics company GlobalData.

A key element of this investment is Europe’s first Lilly Gateway Labs, an innovation accelerator supporting early-stage life science ventures. The facility will provide advanced lab space, mentorship, and financial support to help start-ups develop transformative medicines, bolstering a sector that already supports over 300,000 UK jobs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK